Arvinas, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.arvinas.com

Moat Score
Safety Score

Market Cap $1.71B
PE -6
Debt $1.00M
Cash $85.20M
EV $1.63B
FCF -$259.90M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$308.60M
EBIT	-$306.00M
ROE	-53%
ROA	-26%
FCF	-$259.90M
Equity	$586.00M
Growth Stability	1
PE	-5.55
PB	2.92
P/FCF	-6.59
P/S	10.63
Price/Cash	0.05
Debt/Equity	0
Debt/FCF	-0
Net Margins	-75%
Op. Margins	-190%
Sales Growth YoY	196%
Sales Growth QoQ	34%
Sales CAGR	49%
FCF CAGR	2%
Equity CAGR	32%
Earnings Growth YoY	-23%

Earnings Growth QoQ	40%
Sales CAGR 5Y	46%
FCF CAGR 5Y	-0%
Equity CAGR 5Y	19%
Earnings CAGR 3Y	22%
Sales CAGR 3Y	22%
Equity CAGR 3Y	-8%
Market Cap	$1.71B
Revenue	$161.10M
Assets	$1.17B
Total Debt	$1.00M
Cash	$85.20M
Shares Outstanding	68.7M
EV	1.63B
Moat Score	1%
Safety Score	65%
Working Capital	873.6M
Current Ratio	4.17
Shares Growth 3y	12%
Equity Growth QoQ	-2%
Equity Growth YoY	28%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

SEC Filings

Direct access to Arvinas, Inc. (ARVN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Arvinas, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Arvinas, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Arvinas, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Arvinas, Inc..

Years

Calculation mode

= -$3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$260M	-$265M	-$270M	-$275M	-$281M	-$286M	-$292M	-$298M	-$303M	-$309M	-$315M	-$3.2B
DCF		-$241M	-$223M	-$207M	-$192M	-$178M	-$165M	-$153M	-$142M	-$131M	-$122M	-$1.2B
Value	-$3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-378%	-2K%	-164%	-547%	-409%	-215%	-468%	-75%
ROA	-	-22%	-17%	-16%	-12%	-20%	-28%	-26%
ROE	-	-175%	-31%	-19%	-24%	-50%	-56%	-53%

Bad Net Margins (-75.32%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.12	-0.04	-0.02	0	-0	-0	-0
Debt over Equity	-0.01	0.02	0.01	0	0	0	0	0
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	89%	200%	-49%	114%	181%	-40%	46%
Earnings YoY growth	-	738%	-71%	70%	60%	48%	30%	-
Equity YoY growth	-	-323%	66%	183%	22%	-28%	17%	19%
FCF YoY growth	-	-562%	147%	105%	-677%	-151%	25%	-0%